Alliance will provide expertise and training for new diabetes center in Nanjing, China
Boston, Ma. – (September 18, 2017) – Joslin Diabetes Center, the world’s preeminent diabetes care and research center, today announced it has signed an agreement with China Horae Capital Management Group Co., Ltd. to advise the Horae Nanjing Diabetes Center project currently in development in the city of Nanjing, China. Initial work for Joslin experts will focus on providing guidance on the scope of the new center and training key leadership. Following that, Joslin experts will help develop the Center’s inpatient and outpatient care models, create the educational curriculum for patients and educate the center’s caregivers.
“We are excited to partner with Joslin Diabetes Center to bring Joslin’s world-renowned best practices in diabetes prevention, treatment and management to the people of Nanjing. This is just the beginning; we hope to eventually spread what we learn from the experts at Joslin to our other locations throughout China,” said Yuet Chai, Chairman, China Horae Capital Management Group Co., Ltd.
“Joslin Diabetes Center is thrilled to be partnering with China Horae Capital Management Group Co., Ltd. on this project,” said Peter S. Amenta, M.D., Ph.D., President and CEO of Joslin. “China is experiencing a dramatic increase in the number of people with diabetes. We believe the collaboration between Joslin and Horae will help curb the complications stemming from diabetes and will make a huge impact on the quality of life for the people of Nanjing.”
About China Horae Capital Management Group Co., Ltd.
China Horae Capital Management Group Co., Ltd. aims to build a full range of leading international, high-tech health industry clusters with innovative business models and advanced management concepts. These clusters built with multiple perspectives including research, education, technology transfer, industrial incubation, medical services and financial capital, will form a comprehensive industrial ecological chain, and serve to boost China’s health industry to achieve leapfrog development through the combination of cutting-edge biotechnology and industrial capital.